**Question:** Gyrate Atrophy patient with defective ornithine aminotransferase will be benefited by

A. L-Ornithine supplementation
B. L-Arginine supplementation
C. L-Alanine supplementation
D. None of the above

**Correct Answer:** A. L-Ornithine supplementation

**Core Concept:**
Gyrate Atrophy is a rare autosomal recessive disorder of the retinal pigment epithelium (RPE) characterized by progressive vision loss, photophobia, and chorioretinal atrophy. It is primarily caused by mutations in the OTC gene, encoding ornithine aminotransferase (OAT), an enzyme involved in the urea cycle. The defective OAT leads to the accumulation of toxic substances such as ornithine, citrulline, and arginine.

**Why the Correct Answer is Right:**
In Gyrate Atrophy patients with defective ornithine aminotransferase, the impaired OAT enzyme leads to an imbalance in the urea cycle, causing the accumulation of toxic substances like ornithine, citrulline, and arginine. To correct this imbalance, L-Ornithine supplementation is recommended, as it is a precursor to citrulline and arginine production in the urea cycle. By providing the deficient enzyme substrate, L-Ornithine supplementation helps to restore the balance of these amino acids, reducing the toxic buildup and potentially slowing down the progression of the disease.

**Why Each Wrong Option is Incorrect:**

**Option B (L-Arginine supplementation):**
Arginine is an amino acid that is produced from ornithine in the urea cycle. While L-Arginine supplementation may help in reducing the toxic buildup of ornithine, citrulline, and arginine in the long term, it does not directly address the underlying issue of defective ornithine aminotransferase enzyme. Therefore, L-Arginine supplementation is not the optimal treatment for Gyrate Atrophy patients with defective OAT.

**Option C (L-Alanine supplementation):**
L-Alanine is an amino acid that is not directly involved in the urea cycle or the production of ornithine, citrulline, and arginine. Therefore, L-Alanine supplementation does not address the primary issue in Gyrate Atrophy patients with defective ornithine aminotransferase enzyme.

**Option D (None of the above):**
Given that L-Ornithine supplementation is essential for correcting the urea cycle imbalance and reducing the toxic amino acids, choosing none of the above is incorrect. The disease is primarily caused by a defective ornithine aminotransferase enzyme, and supplementing L-Ornithine addresses this issue directly.

**Clinical Pearl:**
Gyrate Atrophy is a rare autosomal recessive disorder primarily affecting the RPE (Retinal Pigment Epithelial) cells, leading to secondary effects on vision and the eyes. Early diagnosis and treatment with